Influenza and other respiratory viruses · 2025
Seroprevalence Trends of Antibodies to SARS-CoV-2 in South Korea, 2021-2022: A Repeated Cross-Sectional Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Ah-Ra, Achangwa Chiara, Do Hyeon Nam, Jang Eun Young, Nam Yukyung, Cho Seonghui, Kim Taegu, Jeong Hye-Sook, Rhie Gi-Eun, Oh Kyungwon, Kwon Seunghyun Lewis, Lee Seunghyeon, Lee Junewoo, Ryu Sukhyun
Аннотация
BACKGROUND: Monitoring immunity levels nationwide and identifying disparities are important to prepare for future pandemics. However, data regarding changes in the seroprevalence of SARS-CoV-2 and disparities in consecutive epidemic waves using existing surveillance systems are limited.
METHODS: We conducted a cross-sectional serosurvey using 11,506 residual serum samples collected from the Korean National Health and Nutrition Examination Survey between January 2021 and December 2022. Antibodies to the SARS-CoV-2 spike (anti-S) protein, indicative of vaccination or past infection of SARS-CoV-2, and nucleocapsid (anti-N) protein, indicating infection, were quantified. Then, we applied post-stratification weighting through the bootstrap resampling based on the age and sex distribution of the South Korean population. We used regression models to identify any disparities in the seropositivity prevalence ratio (PR) across different epidemic waves of SARS-CoV-2 and demographics in the population.
RESULTS: We identified that the anti-S seropositivity gradually increased after the COVID-19 vaccination rollout, whereas anti-N seropositivity increased after the SARS-CoV-2 Omicron variant was introduced in Korea. Anti-S seropositivity PR was 0.12-0.76 times lower in individuals < 18 years than in elderly individuals ≥ 65 years during Waves 4-5 (July 2021 to June 2022). Anti-N seropositivity PR was 1.25-1.83 times higher in individuals less than 64 years than in elderly individuals during Waves 5-7 (January 2022 to December 2022).
CONCLUSIONS: Our findings provide insights into the dynamic changes in immunity levels among the Korean population after the COVID-19 vaccine rollout and the introduction of the Omicron variant. Identifying the disparity in seroprevalence in the study population during the pandemic by using the existing surveillance system provides helpful information to develop future pandemic preparedness plans for the population.
METHODS: We conducted a cross-sectional serosurvey using 11,506 residual serum samples collected from the Korean National Health and Nutrition Examination Survey between January 2021 and December 2022. Antibodies to the SARS-CoV-2 spike (anti-S) protein, indicative of vaccination or past infection of SARS-CoV-2, and nucleocapsid (anti-N) protein, indicating infection, were quantified. Then, we applied post-stratification weighting through the bootstrap resampling based on the age and sex distribution of the South Korean population. We used regression models to identify any disparities in the seropositivity prevalence ratio (PR) across different epidemic waves of SARS-CoV-2 and demographics in the population.
RESULTS: We identified that the anti-S seropositivity gradually increased after the COVID-19 vaccination rollout, whereas anti-N seropositivity increased after the SARS-CoV-2 Omicron variant was introduced in Korea. Anti-S seropositivity PR was 0.12-0.76 times lower in individuals < 18 years than in elderly individuals ≥ 65 years during Waves 4-5 (July 2021 to June 2022). Anti-N seropositivity PR was 1.25-1.83 times higher in individuals less than 64 years than in elderly individuals during Waves 5-7 (January 2022 to December 2022).
CONCLUSIONS: Our findings provide insights into the dynamic changes in immunity levels among the Korean population after the COVID-19 vaccine rollout and the introduction of the Omicron variant. Identifying the disparity in seroprevalence in the study population during the pandemic by using the existing surveillance system provides helpful information to develop future pandemic preparedness plans for the population.